Thursday, April 18, 2019 7:12:23 AM
7:00 am ET April 18, 2019 (MarketWatch)
Share
Shares of Mustang Bio Inc. (MBIO) blasted off to a near 4-fold gain (up 257%) in premarket trade Thursday, after the biopharmaceutical company said it entered a licensing agreement with St. Jude Children's Research Hospital to develop the lentiviral gene therapy for the treatment of "bubble boy" disease (XSCID) for commercial use. Data from a phase 1/2 clinical trial evaluating the safety and efficacy of a lentiviral vector to transfer a normal copy of the IL2RG gene to bone marrow stem cells in newly diagnosed infants under the age of two with XSCID, showed that bone marrow harvest, busulfan conditioning and cell infusion were well tolerated, all patients cleared previous infections and are growing normally and most patients were discharged from the hospital within one month. "The results have been very good thus far," said Ewelina Mamcarz, assistant member at St. Jude. "We've been able to restore a full immune system pretty quickly." Mustang Bio's stock, which is on track to open at a 1-year high, was down 9.5% year to date through Wednesday. In comparison, the iShares Nasdaq Biotechnology ETF (IBB) has gained 9.0% and the S&P 500 has advanced 15.7%.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
April 18, 2019 07:00 ET (11:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
New York Yankees and Duke Basketball
Recent MBIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:30:51 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 09:08:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:01:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/30/2024 04:15:12 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/19/2024 09:26:16 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 07/10/2024 08:41:37 PM
- Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/21/2024 08:01:58 PM
- Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/20/2024 12:00:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/20/2024 12:00:26 PM
- Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy • GlobeNewswire Inc. • 06/17/2024 12:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:00:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 12:35:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 12:33:33 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/31/2024 09:09:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:15:26 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/13/2024 10:01:30 AM
- Mustang Bio Announces Closing of $4 Million Public Offering • GlobeNewswire Inc. • 05/02/2024 08:01:07 PM
- Mustang Bio Announces Pricing of $4 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 12:00:07 AM
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases • GlobeNewswire Inc. • 03/28/2024 01:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:30:31 PM
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/11/2024 08:05:12 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:02:09 PM
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma • GlobeNewswire Inc. • 03/07/2024 12:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:57 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM